NMN Benefits: What Studies Report

Nicotinamide mononucleotide (NMN) is a nicotinamide-containing nucleotide studied as a precursor to nicotinamide adenine dinucleotide (NAD+). Most of the interest in NMN comes from the observation that NAD+ concentrations decline with age in multiple tissues, a theme reviewed in detail in a 2024 overview of NAD+ metabolism and the challenges of targeting it therapeutically (PMID 39026037). This page summarises, by outcome domain, what published studies measured and reported — not what NMN does for any individual.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here describes a protocol, and no finding below should be read as a promise of an outcome.

How to Read the NMN Evidence Base

The literature splits into three tiers that are easy to conflate. A 2024 review of human trials of candidate anti-aging interventions placed NMN among compounds with small, short-duration human datasets relative to the volume of preclinical claims made about them (PMID 38181790). A 2023 update on NMN human clinical trials similarly assembled the published trials to date and examined their safety reporting and anti-aging endpoints (PMID 37619764), and a 2023 review of NAD+-boosting dietary supplements in humans described current knowledge and the directions the authors considered unresolved (PMID 37068054).

• Human randomised trials — a limited set, mostly weeks to a few months, often in healthy middle-aged or older adults.
• Animal studies — mice and rats, where lifespan, fertility and organ-level endpoints can be measured directly; results do not transfer automatically to people.
• Cell and mechanistic work — in-vitro systems that explain pathways but say nothing about clinical benefit.

Evidence Tiers by Outcome Domain

NAD+ Levels: The Most Consistently Measured Outcome

The endpoint most human NMN trials were designed around is not a disease outcome at all — it is blood NAD+ concentration. A randomised, multicentre, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial in healthy middle-aged adults reported dose-related changes in blood NAD+ alongside safety and efficacy measures (PMID 36482258). A 2024 review of NAD+ boosting strategies placed NMN among several precursor approaches evaluated for their capacity to raise NAD+ and discussed how those strategies differ mechanistically (PMID 39693020).

Researchers have repeatedly noted that raising a biomarker is not the same as improving health. The 2024 review of regulation and challenges in targeting NAD+ metabolism emphasised exactly this gap between pathway modulation and demonstrated clinical effect (PMID 39026037).

Physical Function and Exercise Capacity

The randomised dose-dependent trial in healthy middle-aged adults included functional measures alongside blood NAD+ and reported dose-related findings on walking-related performance in its efficacy assessment (PMID 36482258). The 2023 update on NMN human clinical trials collected this and other trials and discussed the consistency — and inconsistency — of antiaging-related endpoints across them (PMID 37619764).

Readers should note how modest this evidence base is. The 2024 review of human anti-aging trials described the overall field as characterised by short trials and surrogate endpoints rather than long-term functional outcomes (PMID 38181790).

Insulin Sensitivity and Metabolic Measures

One of the most cited NMN human studies examined postmenopausal women with prediabetes and reported that NMN supplementation increased muscle insulin sensitivity, with the study also reporting muscle signalling and remodelling changes (PMID 33888596). That trial was small and conducted in one specific population; researchers did not report that the finding generalised to healthy men, younger adults or people without prediabetes (PMID 33888596).

The 2023 review of NAD+-boosting compounds in humans discussed metabolic endpoints among the outcomes assessed in the supplement literature and highlighted where results had not replicated (PMID 37068054).

Lifespan and Healthspan: Animal Evidence

Claims about NMN and longevity trace primarily to rodent work. A long-term mouse study reported that NMN treatment increased lifespan and healthspan in a sex-dependent manner (PMID 38979132). That report was a bioRxiv preprint, meaning it had not completed journal peer review at the time of posting, and it was conducted in mice — not humans (PMID 38979132).

No human study in the verified set measured lifespan. The 2024 review of human anti-aging medicine trials discussed why lifespan endpoints remain impractical in human research and why surrogate markers dominate instead (PMID 38181790).

Fertility and Reproductive Aging: Mouse Studies

Two 2020 mouse studies are the basis for most fertility discussion. One reported that NAD+ repletion rescued female fertility during reproductive aging in mice (PMID 32049001). The other reported that NMN supplementation reversed the declining quality of maternally aged oocytes (PMID 32755581).

Both were animal studies. Neither established an effect on human fertility, live birth rates or assisted-reproduction outcomes, and neither study reported human data (PMID 32049001, PMID 32755581).

Cardiovascular Outcomes

A 2021 review in Circulation examined NAD+ metabolism in cardiac health, aging and disease, describing the pathways through which NAD+ availability has been linked to cardiac function (PMID 34843394). That review was a synthesis of mechanistic and preclinical work rather than a report of a human cardiovascular outcome trial for NMN (PMID 34843394). The broader review of NAD+ boosting strategies likewise framed cardiac applications as an area of ongoing investigation (PMID 39693020).

Immune Aging and Cellular Senescence

NMN is frequently discussed alongside cellular senescence. A 2025 translational study reported that interferon-induced senescent CD8+ T cells reduced anti-PD1 immunotherapy efficacy in early triple-negative breast cancer, work that sits in the senescence-and-NAD+ research area rather than in NMN supplementation research (PMID 40929245). It does not establish an immune benefit of NMN supplementation in healthy people (PMID 40929245).

Claimed Benefits With Weak or Absent Evidence

Several outcomes commonly attached to NMN are not supported by the human studies in this citation set. Stated plainly:

• Cognition and memory. No human trial in the verified set reported cognitive outcomes; the 2023 update on NMN human clinical trials catalogued the endpoints that have actually been studied (PMID 37619764).
• Skin appearance, hair and "energy". These were not endpoints in the randomised dose-dependent trial in healthy middle-aged adults (PMID 36482258).
• Weight loss. The prediabetic-women trial reported muscle insulin sensitivity, not body-weight reduction, as its finding (PMID 33888596).
• Disease treatment. The 2024 review of targeting NAD+ metabolism described translational challenges that remain unresolved rather than established clinical indications (PMID 39026037).

Tolerability in Human Trials: What Studies Report

The randomised, multicentre, double-blind, placebo-controlled dose-dependent trial in healthy middle-aged adults assessed safety as a co-primary concern alongside efficacy and reported on tolerability across its dose groups (PMID 36482258). The 2023 update on the safety and antiaging effects of NMN in human clinical trials reviewed safety reporting across the published trials (PMID 37619764), and the 2023 review of NAD+-boosting dietary supplements in humans discussed the limits of current safety knowledge, particularly for long-term use (PMID 37068054).

Researchers across these publications consistently framed trial durations as short relative to the long-term use patterns discussed in popular coverage (PMID 37068054, PMID 38181790).

Limitations Named by the Researchers Themselves

1. Small samples and short durations. The 2024 human anti-aging trials review characterised the field by these constraints (PMID 38181790).
2. Surrogate endpoints. Blood NAD+ was the primary readout in much of the human work summarised in the NAD+ boosting strategies review (PMID 39693020).
3. Species gap. Lifespan and fertility findings came from mice (PMID 38979132, PMID 32049001).
4. Population specificity. The insulin-sensitivity result was reported in prediabetic postmenopausal women specifically (PMID 33888596).
5. Mechanistic uncertainty. The 2024 NAD+ metabolism review described open questions about how precursor supply translates into tissue-level effects (PMID 39026037).

Bottom Line From the Cited Literature

Across the studies cited on this page, the best-supported human finding is that NMN supplementation raised blood NAD+ in a dose-related manner in a randomised trial of healthy middle-aged adults, with additional functional measures assessed in the same trial (PMID 36482258). A separate trial reported increased muscle insulin sensitivity in prediabetic women (PMID 33888596), while longevity and fertility claims rest on mouse data (PMID 38979132, PMID 32755581). Reviews of the human literature have consistently described the evidence as early-stage (PMID 37619764). Again, this page is for educational purposes only and is not medical advice; consult a licensed physician about any supplement or health question.

References

• Human trials exploring anti-aging medicines (Cell Metabolism, 2024)
• The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial (GeroScience, 2023)
• The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update (Advances in Nutrition, 2023)
• Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women (Science, 2021)
• NAD(+) Boosting Strategies (Sub-cellular Biochemistry, 2024)
• Regulation of and challenges in targeting NAD(+) metabolism (Nature Reviews Molecular Cell Biology, 2024)
• NAD(+) Repletion Rescues Female Fertility during Reproductive Aging (Cell Reports, 2020)
• Nicotinamide Mononucleotide Supplementation Reverses the Declining Quality of Maternally Aged Oocytes (Cell Reports, 2020)
• Interferon-induced senescent CD8(+) T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer (Science Translational Medicine, 2025)
• NAD(+) Metabolism in Cardiac Health, Aging, and Disease (Circulation, 2021)
• Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions (Journals of Gerontology Series A, 2023)
• Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner (bioRxiv, 2024)